CD274 and cancer: Immune checkpoint inhibitors (CPI) targeting the programmed cell death protein 1 (PD-1) receptor and its ligand, programmed cell death ligand 1 (PD-L1), have transformed cancer treatment to become the standard of care in various advanced solid malignancies (1, 2).